Antimicrobial peptide A9K as a gene delivery vector in cancer cells
- PMID: 38467336
- DOI: 10.1016/j.ejpb.2024.114244
Antimicrobial peptide A9K as a gene delivery vector in cancer cells
Abstract
Designed peptides are promising biomaterials for biomedical applications. The amphiphilic cationic antimicrobial peptide (AMP), A9K, can self-assemble into nano-rod structures and has shown cancer cell selectivity and could therefore be a promising candidate for therapeutic delivery into cancer cells. In this paper, we investigate the selectivity of A9K for cancer cell models, examining its effect on two human cancer cell lines, A431 and HCT-116. Little or no activity was observed on the control, human dermal fibroblasts (HDFs). In the cancer cell lines the peptide inhibited cellular growth through changes in mitochondrial morphology and membrane potential while remaining harmless towards HDFs. In addition, the peptide can bind to and protect nucleic acids while transporting them into both 2D cultures and 3D spheroids of cancer cells. A9K showed high efficiency in delivering siRNA molecules into the centre of the spheroids. A9K was also explored in vivo, using a zebrafish (Danio rerio) development toxicity assay, showing that the peptide is safe at low doses. Finally, a high-content imaging screen, using RNA interference (RNAi) targeted towards cellular uptake, in HCT-116 cells was carried out. Our findings suggest that active cellular uptake is involved in peptide internalisation, mediated through clathrin-mediated endocytosis. These new discoveries make A9K attractive for future developments in clinical and biotechnological applications.
Keywords: Endocytosis; Peptides; Toxicity; Transfection; siRNA.
Copyright © 2024 Elsevier B.V. All rights reserved.
Conflict of interest statement
Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
Similar articles
-
Designed Antitumor Peptide for Targeted siRNA Delivery into Cancer Spheroids.ACS Appl Mater Interfaces. 2021 Oct 27;13(42):49713-49728. doi: 10.1021/acsami.1c14761. Epub 2021 Oct 17. ACS Appl Mater Interfaces. 2021. PMID: 34657415
-
Rationally designed cationic amphiphilic peptides for selective gene delivery to cancer cells.Int J Pharm. 2022 Apr 5;617:121619. doi: 10.1016/j.ijpharm.2022.121619. Epub 2022 Feb 23. Int J Pharm. 2022. PMID: 35218898
-
Cellular delivery of small interfering RNA by a non-covalently attached cell-penetrating peptide: quantitative analysis of uptake and biological effect.Nucleic Acids Res. 2006;34(22):6561-73. doi: 10.1093/nar/gkl941. Epub 2006 Nov 28. Nucleic Acids Res. 2006. PMID: 17135188 Free PMC article.
-
Functional peptides for siRNA delivery.Adv Drug Deliv Rev. 2017 Feb;110-111:157-168. doi: 10.1016/j.addr.2016.08.004. Epub 2016 Aug 13. Adv Drug Deliv Rev. 2017. PMID: 27530388 Free PMC article. Review.
-
Peptide carriers to the rescue: overcoming the barriers to siRNA delivery for cancer treatment.Transl Res. 2019 Dec;214:92-104. doi: 10.1016/j.trsl.2019.07.010. Epub 2019 Jul 29. Transl Res. 2019. PMID: 31404520 Free PMC article. Review.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical